Analyst picks & changes

Alpha-Beta Technology Inc.

UBS Securities analyst Marc Ostro said that changes in the Phase III protocol of Alpha-Beta Technology Inc.'s Betafectin anti-infective in high-risk abdominal surgery patients, as a result of the FDA's review, will change the

Read the full 367 word article

How to gain access

Continue reading with a
two-week free trial.